Soley Therapeutics closed a $200 million Series C to advance its cell‑stress sensing platform and multiple clinical candidates, with a particular focus on oncology. The company plans IND filings and to push its lead AML candidate, SOL‑001, into first‑in‑human trials in 2026. CEO Yerem Yeghiazarians described the approach as targeting upstream cellular stress pathways to reshape cell states across cancer and neurodegeneration. Investors named include Doug Leone Family Fund and Breyer Capital, signaling large institutional support for mechanism‑agnostic, biology‑driven platforms. The round reflects continuing investor interest in platform companies that propose broad‑application modalities spanning oncology and degenerative disease, and it funds IND‑enabling and early clinical work that could drive value inflection points over the next 12–24 months.